WO2012052463A1 - Cysteine and food intake - Google Patents
Cysteine and food intake Download PDFInfo
- Publication number
- WO2012052463A1 WO2012052463A1 PCT/EP2011/068231 EP2011068231W WO2012052463A1 WO 2012052463 A1 WO2012052463 A1 WO 2012052463A1 EP 2011068231 W EP2011068231 W EP 2011068231W WO 2012052463 A1 WO2012052463 A1 WO 2012052463A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cysteine
- nutritional composition
- accordance
- composition
- food
- Prior art date
Links
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 235000018417 cysteine Nutrition 0.000 title claims abstract description 62
- 235000012631 food intake Nutrition 0.000 title claims description 24
- 230000037406 food intake Effects 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 235000016709 nutrition Nutrition 0.000 claims abstract description 30
- 208000002720 Malnutrition Diseases 0.000 claims abstract description 14
- 230000001071 malnutrition Effects 0.000 claims abstract description 14
- 235000000824 malnutrition Nutrition 0.000 claims abstract description 14
- 208000015380 nutritional deficiency disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 208000035475 disorder Diseases 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 230000035764 nutrition Effects 0.000 claims abstract description 6
- 230000037396 body weight Effects 0.000 claims description 15
- 206010061428 decreased appetite Diseases 0.000 claims description 15
- 208000022531 anorexia Diseases 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 13
- 235000018102 proteins Nutrition 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 235000012054 meals Nutrition 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 235000019789 appetite Nutrition 0.000 claims description 5
- 230000036528 appetite Effects 0.000 claims description 5
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 claims description 4
- ZFAHNWWNDFHPOH-YFKPBYRVSA-N S-allylcysteine Chemical compound OC(=O)[C@@H](N)CSCC=C ZFAHNWWNDFHPOH-YFKPBYRVSA-N 0.000 claims description 4
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- -1 gamma-glutamyl- cysteine ester Chemical class 0.000 claims description 4
- 108010068906 gamma-glutamylcysteine Proteins 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- QJKNWVUQWOQIMO-UKSKFBDSSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;(2r)-2-amino-3-sulfanylpropanoic acid Chemical compound SC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O QJKNWVUQWOQIMO-UKSKFBDSSA-N 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- ZFAHNWWNDFHPOH-UHFFFAOYSA-N S-Allyl-L-cystein Natural products OC(=O)C(N)CSCC=C ZFAHNWWNDFHPOH-UHFFFAOYSA-N 0.000 claims description 2
- ULXKXLZEOGLCRJ-BYPYZUCNSA-N S-ethyl-L-cysteine zwitterion Chemical compound CCSC[C@H](N)C(O)=O ULXKXLZEOGLCRJ-BYPYZUCNSA-N 0.000 claims description 2
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 claims description 2
- WAAGBMYUYFBZIW-UHFFFAOYSA-N S-propylcysteine Chemical compound CCCSCC(N)C(O)=O WAAGBMYUYFBZIW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001408 amides Chemical group 0.000 claims description 2
- 150000001944 cysteine derivatives Chemical class 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 150000002019 disulfides Chemical class 0.000 claims description 2
- 150000002148 esters Chemical group 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 235000019553 satiation Nutrition 0.000 claims description 2
- 235000019627 satiety Nutrition 0.000 claims description 2
- 230000036186 satiety Effects 0.000 claims description 2
- RITKHVBHSGLULN-CRCLSJGQSA-N γ-glutamylcysteine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](CS)C(O)=O RITKHVBHSGLULN-CRCLSJGQSA-N 0.000 claims description 2
- QWWKUMCQWWYODU-VKHMYHEASA-N (2r)-3-hydroxysulfanyl-2-[methyl(sulfanyl)amino]propanoic acid Chemical compound CN(S)[C@H](C(O)=O)CSO QWWKUMCQWWYODU-VKHMYHEASA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 40
- 235000005911 diet Nutrition 0.000 description 16
- 230000037213 diet Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- 230000032683 aging Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IOOMXPHYBWAZAQ-REOHCLBHSA-N (2r)-3-sulfanyl-2-(sulfanylamino)propanoic acid Chemical compound OC(=O)[C@H](CS)NS IOOMXPHYBWAZAQ-REOHCLBHSA-N 0.000 description 1
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FVRWSIPJNWXCEO-YUMQZZPRSA-N S-acetylglutathione Chemical compound OC(=O)CNC(=O)[C@H](CSC(=O)C)NC(=O)CC[C@H](N)C(O)=O FVRWSIPJNWXCEO-YUMQZZPRSA-N 0.000 description 1
- 108700017742 S-acetylglutathione Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000001398 anti-anorexic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229960004272 bucillamine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012628 flowing agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition.
- One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment or prevention of malnutrition and disorders related thereto.
- Such a composition may in particular, but not exclusively, be useful for the elderly population.
- Anorexia is the decreased sensation of appetite. Many possible causes exist for a decreased appetite, some of which may indicate a serious clinical condition, or pose a significant risk. Oftentimes anorexia is a consequence of other illnesses. Under such circumstances malnutrition is a significant problem since it will delay the recovery process and may even prevent a full recovery.
- Anorexia is often present in the ageing population. Despite the increase in body fat and obesity that occurs with aging, there is a linear decrease in food intake over the life span. This may be explained by decreased physical activity and an altered metabolism with aging. Ageing-associated anorexia may have substantial adverse effects. The age-associated physiologic reduction in appetite and food intake has been termed “the anorexia of aging”. "Physiological' anorexia and weight loss of ageing predispose to pathological weight loss and malnutrition. This physiologic anorexia is caused for example by an altered hormonal and neurotransmitter regulation of food intake. Marked weight loss in the elderly drives morbidity and increased mortality, has a negative impact on the quality of life and contributes to frailty. Today, anorexia is often treated by administration of a variety of medicaments, some of which may have unwanted side effects .
- cysteine can be used, e.g. as part of a composition for enteral nutrition or a food product, to maintain or improve food intake, for example in the elderly.
- cysteine exhibits an anti-anorexic property, for example an anti ageing-associated anorexia property. Such effect was not observed with alanine- supplemented diet (control diet). To the inventor's best knowledge, this is the first description of a beneficial effect of cysteine on food intake. Consequently, providing cysteine-rich diet or adding cysteine to a food product, for example in a quantity higher than the normal requirement would allow counteracting the decrease in food consumption that occurs, e.g., in the elderly.
- anorexia e.g. chemotherapy, infection, anorexia nervosa, or stress conditions.
- cysteine may be used to treat or prevent anorexia and related conditions.
- cysteine may also be used in clinical products to control food intake, for example.
- one embodiment of the present invention is a nutritional composition enriched in cysteine.
- “Enriched” in cysteine means that cysteine was either added to a nutritional composition or that a food composition is treated in a way that its natural cysteine content per gram is increased.
- a composition is further considered “enriched” in cysteine if the composition contains cysteine in an amount that exceeds the recommended daily intake (RDI) .
- the recommended daily intake for cysteine for infants (0-12 months) is 45 mg/kg body weight; for children (1-17 years) 22 mg/kg body weight; and for adults (> 18 years) 10 mg/kg body weight.
- Cysteine may also be provided in the form of a cysteine precursor selected from the group consisting of cysteine bound in a protein or a peptide hydrolysate or a peptide, for example gamma-glutamyl-cysteine, or an ther form of peptide, for example gamma-glutamyl-cysteine ester, mixed disulfides such as L-cysteine-glutathione cysteine prodrugs, N-acetyl- cysteine (free form, amide or ester forms), S-allyl-cysteine, S-methyl-cysteine, S-ethyl-cysteine , S-propyl-cysteine, TCA ( thiazelidineScarboxylic acid) , OTC ( L-2-Oxothiazolidine-4- carboxylate) , bucillamine glutathione and glutathione esters (monomethyl, monoethyl, diethyl, iso
- the present invention also relates to the use of cysteine for the preparation of a composition to treat and/or prevent malnutrition and/or disorders related thereto.
- composition of the present invention may be additionally or alternatively for use in increasing food intake.
- composition of the present invention may also be used for decreasing satiety and/or satiation.
- the inventors found that the administration of the composition of the present invention allowed to significantly increase food intake.
- the composition of the present invention may also be used for increasing appetite.
- composition of the present invention allows increasing the willingness to eat as well as the total quantity of ingested food.
- any disorder related to malnutrition may be treated by administration of the composition of the present invention.
- the disorder related to malnutrition may be selected from the group consisting of anorexia, anorexia nervosa, cachexia, inflammatory diseases associated with decreased food intake, or combinations thereof.
- Low-grade inflammation appears to be an important parameter in the development of the homeosteny, for example associated with ageing.
- Age-associated low-grade inflammation may cause an increase mortality and morbidity, such as body weight loss.
- the present invention provides a new nutritional strategy to counterbalance such negative effects of low-grade inflammation that may occur in the elderly, for example.
- the composition may be to be administered to the elderly.
- a subject is considered as “elderly” or “aged” if it has surpassed the first half of its average expected lifespan in its country of origin, preferably, if it has surpassed the first two thirds of the average expected lifespan in its country of origin, more preferably if it has surpassed the first three quarters of the average expected lifespan in its country of origin, most preferred if it has surpassed the first four fifths of the average expected lifespan in its country of origin.
- composition of the present invention may be to be administered to a person at the age of at least 50 years, at least 60 years, at least 70 years or at least 80 years.
- composition of the present invention may also be to be administered to pets, for example aged pets.
- composition in accordance with the present invention may be for use in the treatment or prevention of an age related decrease in food intake.
- compositions of the present invention will typically contain a protein fraction, a lipid fraction and a carbohydrate fraction.
- the protein fraction may comprise at least 3.0 weight-%, at least 4 weight-%, at least 5 weight-%, at least 7 weight-% or at least 10 weight-% cysteine.
- a subject suffers from an impaired functioning of the gastro-intestinal tract, it may be preferred if for example at least in part a protein source is used that is pre-hydrolyzed.
- MCT medium chain triglycerides
- cysteine may typically be administered in a daily dose in the range of about 0.03 to 0.15 g/kg body weight, for example 0.05 to 0.12 g/kg body weight.
- the composition may contain cysteine in an amount of at least 2 g/kg dry weight, at least 4 g/kg dry weight, at least 6 g/kg dry weight, at least 8 g/kg dry weight, or at least 10 g/kg dry weight.
- cysteine from any source may be used in the framework of the present invention. Chemically pure cysteine has the advantage of being available in high purity and concentrations allowing a very precise dosing.
- cysteine may also be provided from natural sources.
- cysteine may be provided from animal sources such as pork, sausage meat, chicken, turkey, duck, luncheon meat, eggs, milk, milk proteins, whey protein, ricotta, cottage cheese, and/or yogurt; and/or from vegan sources such as red peppers, garlic, onions, broccoli, Brussels sprouts, oats, granola, and/or wheat germ.
- compositions of the present invention may have a caloric density of at least 0.5 kcal/g dry weight. Some people with an overall low food intake have problems to digest high caloric food. For such people low caloric formulations are preferred. Otherwise, increasing food intake has a more pronounced effect if food with a higher caloric density is consumed. Hence, the compositions of the present invention may also have a caloric density of at least 0.8 kcal/g dry weight, at least 1.0 kcal/g dry weight, at least 1.5 kcal/g dry weight, or at least 2.0 kcal/g dry weight.
- about 10 to 40 % of the calories of the composition may be from proteins.
- about 20 to 40 % of the calories of the composition are from proteins.
- the composition may also comprise about 15 to 45 % of the calories of the composition from lipids, and/or about 20 to 70 % of the calories of the composition from carbohydrates.
- the composition may be any kind of composition that is acceptable for human or animal consumption.
- the composition may be selected from the group consisting of a food product, a pet food product, a drink, a pharmaceutical, a nutritional formula, a composition for clinical nutrition, a nutritional powder to be reconstituted by addition of water, a juice or milk, a nutraceutical, a food additive, a food supplement, a dairy product, or a gel.
- Food additive or medicaments may be in the form of tablets, capsules, pastilles or a liquid for example.
- compositions may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc. ) , adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste masking agents, weighting agents, jellifying agents, gel forming agents, antioxidants and antimicrobials .
- protective hydrocolloids such as gums, proteins, modified starches
- binders film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc. ) , adsorbents, carriers, fillers, co-
- They may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
- conventional pharmaceutical additives and adjuvants, excipients and diluents including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
- composition may be to be administered orally, enterally or parenterally.
- oral administration is preferred, since it can be easily done at home, and would consequently allow using the subject matter of the present invention in a private atmosphere. Everybody could easily have access to and use the compositions of the present invention, optionally after consultation with medical personnel.
- enteral administration of the compositions of the present invention may be a preferred option, for example as tube feeding formulation. If oral and/or enteral administration is not possible or not recommended, parenteral administration may be used. Hence, the composition of the present invention may also be in a form suitable for parenteral administration. Such compositions often do not contain a carbohydrate source, for example.
- composition may be to be administered as a meal or in the framework of a meal.
- composition may also to be administered within one hour before or during a meal, for example. As such it may serve as a functional appetizer, for example.
- Figure 1 summarized the experimental design.
- Figure 2 shows Kaplan-Meier survival curves of old rats fed with an alanine (A) and a cysteine (C) diet.
- Figure 3 shows the effect of cysteine supplementation on body weight.
- a to h time points not sharing a common letter are significantly different (Fisher's PLSD, P ⁇ 0.05).
- Figure 4 shows the effect of cysteine supplementation on food intake.
- a to 1 time points not sharing a common letter are significantly different (Fisher's PLSD, P ⁇ 0.05).
- a cohort of male Wistar rats born and breed in a non-specific- pathogen-free animal facility (Unite de Nutrition Comparee, INRA Theix) was used for the study. When rats were 18 month old they were weighted monthly to evaluate their body weight change and blood was sampled in order to quantify inflammatory markers (acute phase proteins: 2-macro gl obul i n and fibrinogen) . At the age of 21 months, rats were divided in two groups matched for body weight, body weight loss, and inflammatory status. Rats were fed with supplemented diets, starting at the age of 21 months and for 14 weeks.
- the cysteine diet consisted in the commercial pelleted diet A04 (SAFE/UAR, Scientific Animal Food and Engineering, Villemoisson-sur-Orge, France) supplemented with 4.0 g of L- cysteine (Sigma) per kg, and the control diet was supplemented with 2.9 g of L-alanine (Jerafrance) per kg ( iso-nitrogenous diets) .
- Experimental diets have been prepared at the Unite Preparation Aliments Experimentaux, INRA Jouy-en-Josas .
- the amino acid composition of the commercial (non-supplemented) diet is presented in Table 1. Table 1. Amino acid composition of the commercial diet (A04 ) .
- Body weight (Fig 3) decreased with time and it became significantly different from the initial value at 7 weeks of supplementation. The decrease accelerated at the end of the experiment since body weights of the two last weeks were different from each of the previous ones.
- cysteine supplemented rats exhibited a higher liver weight than control rats.
- BW body weight
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment and/or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population.
Description
Cysteine and food intake
The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population.
Anorexia is the decreased sensation of appetite. Many possible causes exist for a decreased appetite, some of which may indicate a serious clinical condition, or pose a significant risk. Oftentimes anorexia is a consequence of other illnesses. Under such circumstances malnutrition is a significant problem since it will delay the recovery process and may even prevent a full recovery.
Anorexia is often present in the ageing population. Despite the increase in body fat and obesity that occurs with aging, there is a linear decrease in food intake over the life span. This may be explained by decreased physical activity and an altered metabolism with aging. Ageing-associated anorexia may have substantial adverse effects. The age-associated physiologic reduction in appetite and food intake has been termed "the anorexia of aging". "Physiological' anorexia and weight loss of ageing predispose to pathological weight loss and malnutrition. This physiologic anorexia is caused for example by an altered hormonal and neurotransmitter regulation of food intake. Marked weight loss in the elderly drives morbidity and increased mortality, has a negative impact on the quality of life and contributes to frailty.
Today, anorexia is often treated by administration of a variety of medicaments, some of which may have unwanted side effects .
Consequently, there is a need in the art for a natural way to treat and/or prevent malnutrition and disorders related thereto without unwanted side effects, in particular in the elderly. Ideally, this should be accomplished by a composition that is available to everyone, is liked by the consumers and can be used on a daily basis. The present inventors have addressed this need.
Hence, it was the object of the present invention to improve the state of the art and to provide the art with a composition that achieves the ob ect of the present invention.
The inventors were surprised to see that they could achieve this object by the subject matter of the independent claim. The dependant claims further develop the idea of the present invention.
In particular the inventors have found that cysteine can be used, e.g. as part of a composition for enteral nutrition or a food product, to maintain or improve food intake, for example in the elderly.
The inventors found that cysteine exhibits an anti-anorexic property, for example an anti ageing-associated anorexia property. Such effect was not observed with alanine- supplemented diet (control diet). To the inventor's best knowledge, this is the first description of a beneficial effect of cysteine on food intake. Consequently, providing cysteine-rich diet or adding cysteine to a food product, for example in a quantity higher than the normal requirement would
allow counteracting the decrease in food consumption that occurs, e.g., in the elderly. There are also many health- related conditions are associated with anorexia, e.g. chemotherapy, infection, anorexia nervosa, or stress conditions. Also here cysteine may be used to treat or prevent anorexia and related conditions. Hence, cysteine may also be used in clinical products to control food intake, for example.
Consequently, one embodiment of the present invention is a nutritional composition enriched in cysteine. "Enriched" in cysteine means that cysteine was either added to a nutritional composition or that a food composition is treated in a way that its natural cysteine content per gram is increased. A composition is further considered "enriched" in cysteine if the composition contains cysteine in an amount that exceeds the recommended daily intake (RDI) . The recommended daily intake for cysteine for infants (0-12 months) is 45 mg/kg body weight; for children (1-17 years) 22 mg/kg body weight; and for adults (> 18 years) 10 mg/kg body weight.
Cysteine may also be provided in the form of a cysteine precursor selected from the group consisting of cysteine bound in a protein or a peptide hydrolysate or a peptide, for example gamma-glutamyl-cysteine, or an ther form of peptide, for example gamma-glutamyl-cysteine ester, mixed disulfides such as L-cysteine-glutathione cysteine prodrugs, N-acetyl- cysteine (free form, amide or ester forms), S-allyl-cysteine, S-methyl-cysteine, S-ethyl-cysteine , S-propyl-cysteine, TCA ( thiazelidineScarboxylic acid) , OTC ( L-2-Oxothiazolidine-4- carboxylate) , bucillamine glutathione and glutathione esters (monomethyl, monoethyl, diethyl, isopropyl), glutathione prodrugs, S-acetyl-glutathione, S-pheylacetate-glutathione, and S-hydroxy-mehtyl mercapto L-cysteine.
The composition of the present invention may be for use in the treatment and/or prevention of malnutrition and/or disorders related thereto.
The present invention also relates to the use of cysteine for the preparation of a composition to treat and/or prevent malnutrition and/or disorders related thereto.
The composition of the present invention may be additionally or alternatively for use in increasing food intake.
It may also be used for decreasing satiety and/or satiation. Notably, the inventors found that the administration of the composition of the present invention allowed to significantly increase food intake. Hence, the composition of the present invention may also be used for increasing appetite.
The composition of the present invention allows increasing the willingness to eat as well as the total quantity of ingested food.
Hence, e.g., any disorder related to malnutrition may be treated by administration of the composition of the present invention. For example, the disorder related to malnutrition may be selected from the group consisting of anorexia, anorexia nervosa, cachexia, inflammatory diseases associated with decreased food intake, or combinations thereof.
Low-grade inflammation appears to be an important parameter in the development of the homeosteny, for example associated with ageing. Age-associated low-grade inflammation may cause an increase mortality and morbidity, such as body weight loss. The present invention provides a new nutritional strategy to
counterbalance such negative effects of low-grade inflammation that may occur in the elderly, for example.
In one embodiment of the present invention, the composition may be to be administered to the elderly. A subject is considered as "elderly" or "aged" if it has surpassed the first half of its average expected lifespan in its country of origin, preferably, if it has surpassed the first two thirds of the average expected lifespan in its country of origin, more preferably if it has surpassed the first three quarters of the average expected lifespan in its country of origin, most preferred if it has surpassed the first four fifths of the average expected lifespan in its country of origin.
For example, the composition of the present invention may be to be administered to a person at the age of at least 50 years, at least 60 years, at least 70 years or at least 80 years.
The composition of the present invention may also be to be administered to pets, for example aged pets.
The composition in accordance with the present invention may be for use in the treatment or prevention of an age related decrease in food intake.
The compositions of the present invention will typically contain a protein fraction, a lipid fraction and a carbohydrate fraction. The protein fraction may comprise at least 3.0 weight-%, at least 4 weight-%, at least 5 weight-%, at least 7 weight-% or at least 10 weight-% cysteine.
In case a subject suffers from an impaired functioning of the gastro-intestinal tract, it may be preferred if for example at least in part a protein source is used that is pre-hydrolyzed.
For the same reason it might be preferred if a lipid source containing MCT (medium chain triglycerides) is used. MCTs have the advantage that they are easily absorbed by the body.
In the framework of the present invention cysteine may typically be administered in a daily dose in the range of about 0.03 to 0.15 g/kg body weight, for example 0.05 to 0.12 g/kg body weight.
In order to achieve such daily doses, the composition may contain cysteine in an amount of at least 2 g/kg dry weight, at least 4 g/kg dry weight, at least 6 g/kg dry weight, at least 8 g/kg dry weight, or at least 10 g/kg dry weight. Cysteine from any source may be used in the framework of the present invention. Chemically pure cysteine has the advantage of being available in high purity and concentrations allowing a very precise dosing.
However, cysteine may also be provided from natural sources. For example, cysteine may be provided from animal sources such as pork, sausage meat, chicken, turkey, duck, luncheon meat, eggs, milk, milk proteins, whey protein, ricotta, cottage cheese, and/or yogurt; and/or from vegan sources such as red peppers, garlic, onions, broccoli, Brussels sprouts, oats, granola, and/or wheat germ.
These natural sources allow producing natural and effective food compositions without adding artificially produced compounds. It is also possible to meet specific dietary needs, such as for example for vegetarians or vegans.
The compositions of the present invention may have a caloric density of at least 0.5 kcal/g dry weight. Some people with an overall low food intake have problems to digest high caloric food. For such people low caloric formulations are preferred. Otherwise, increasing food intake has a more pronounced effect if food with a higher caloric density is consumed. Hence, the compositions of the present invention may also have a caloric density of at least 0.8 kcal/g dry weight, at least 1.0 kcal/g dry weight, at least 1.5 kcal/g dry weight, or at least 2.0 kcal/g dry weight.
Typically, about 10 to 40 % of the calories of the composition may be from proteins. As in particularly elderly people often suffer from insufficient protein intake it may be preferred if about 20 to 40 % of the calories of the composition are from proteins.
The composition may also comprise about 15 to 45 % of the calories of the composition from lipids, and/or about 20 to 70 % of the calories of the composition from carbohydrates.
The composition may be any kind of composition that is acceptable for human or animal consumption. For example, the composition may be selected from the group consisting of a food product, a pet food product, a drink, a pharmaceutical, a nutritional formula, a composition for clinical nutrition, a nutritional powder to be reconstituted by addition of water, a juice or milk, a nutraceutical, a food additive, a food supplement, a dairy product, or a gel.
Food additive or medicaments may be in the form of tablets, capsules, pastilles or a liquid for example.
The compositions may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film
forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc. ) , adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste masking agents, weighting agents, jellifying agents, gel forming agents, antioxidants and antimicrobials .
They may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
The composition may be to be administered orally, enterally or parenterally.
In general oral administration is preferred, since it can be easily done at home, and would consequently allow using the subject matter of the present invention in a private atmosphere. Everybody could easily have access to and use the compositions of the present invention, optionally after consultation with medical personnel.
In hospitalized conditions, malnutrition and lack of appetite is often a serious problem that may cause delays in the recovery process. For people not willing to or unable to consume food orally, enteral administration of the compositions of the present invention may be a preferred option, for example as tube feeding formulation.
If oral and/or enteral administration is not possible or not recommended, parenteral administration may be used. Hence, the composition of the present invention may also be in a form suitable for parenteral administration. Such compositions often do not contain a carbohydrate source, for example.
The composition may be to be administered as a meal or in the framework of a meal.
The composition may also to be administered within one hour before or during a meal, for example. As such it may serve as a functional appetizer, for example.
Those skilled in the art will understand that they can freely combine all features of the present invention described herein, without departing from the scope of the invention as disclosed. In particular, features described for the use of the present invention may be applied to the compositions of the present invention and vice versa.
Further advantages and features of the present invention are apparent from the following Examples and Figures.
Figure 1 summarized the experimental design. Figure 2 shows Kaplan-Meier survival curves of old rats fed with an alanine (A) and a cysteine (C) diet. Log-rank test = 0.054, P = 0.816.
Figure 3 shows the effect of cysteine supplementation on body weight. Two-way Anova for repeated measurements: Time (T) : P < 0.0001, Diet (D) : P = 0.915, TxD: P = 0.137. a to h time points not sharing a common letter are significantly different (Fisher's PLSD, P < 0.05).
Figure 4 shows the effect of cysteine supplementation on food intake. Two-way Anova for repeated measurements: Time (T) : P <
0.0001, Diet (D) : P = 0.0002, TxD: P < 0.0001. a to 1 time points not sharing a common letter are significantly different (Fisher's PLSD, P < 0.05).
Examples:
A cohort of male Wistar rats born and breed in a non-specific- pathogen-free animal facility (Unite de Nutrition Comparee, INRA Theix) was used for the study. When rats were 18 month old they were weighted monthly to evaluate their body weight change and blood was sampled in order to quantify inflammatory markers (acute phase proteins: 2-macro gl obul i n and fibrinogen) . At the age of 21 months, rats were divided in two groups matched for body weight, body weight loss, and inflammatory status. Rats were fed with supplemented diets, starting at the age of 21 months and for 14 weeks. The cysteine diet consisted in the commercial pelleted diet A04 (SAFE/UAR, Scientific Animal Food and Engineering, Villemoisson-sur-Orge, France) supplemented with 4.0 g of L- cysteine (Sigma) per kg, and the control diet was supplemented with 2.9 g of L-alanine (Jerafrance) per kg ( iso-nitrogenous diets) . Experimental diets have been prepared at the Unite Preparation Aliments Experimentaux, INRA Jouy-en-Josas . The amino acid composition of the commercial (non-supplemented) diet is presented in Table 1. Table 1. Amino acid composition of the commercial diet (A04 ) .
methionine 2.00 3.26
isoleucine 3.4 5.58
leucine 7.1 11.61
tyrosine 3.2 5.29
phenylalanine 4.4 7.18
lysine 4.5 7.29
histidine 2.3 3.69
arginine 5.6 9.17
Total 91.1 148.46
1- Mortality
Survival curves were generated by Kaplan-Meier method (Fig 2) and compared by the log-rank test in order to analyze the effect of cysteine supplementation on mortality.
Cysteine supplementation did not change the mortality rate.
2- Body weight
Body weight (Fig 3) decreased with time and it became significantly different from the initial value at 7 weeks of supplementation. The decrease accelerated at the end of the experiment since body weights of the two last weeks were different from each of the previous ones.
3- Food intake
Food intake (Fig 4) decreased with time and was lower for the alanine diet. The significant interaction between time and diet reveals that cysteine was able to blunt the decrease in food intake associated with aging. Indeed, food intake significantly decreased by 0.96% per week in the alanine group
(significant linear regression r = 0.88, P < 0.0001) whereas it was unchanged in the cysteine group (r = 0.20, P = 0.50) .
The consumption of the 4 g cysteine supplemented diet blunts the decrease in food intake that occurred when rats were about 22.5 months old suggesting that cysteine exhibit an anti ageing-associated anorexia property.
4- Body weight, skeletal muscle and organ weights
As shown in Table 3, cysteine supplemented rats exhibited a higher liver weight than control rats.
Table 3. Effect of cysteine supplementation on body, skeletal muscle and organ weights
BW: body weight.
Claims
Claims :
Cysteine for use in the treatment and/or prevention of malnutrition and/or disorders related thereto.
Cysteine for use in accordance with claim 1, wherein the cysteine is provided in the form of a cysteine precursor selected from the group consisting of cysteine bound in a protein or a peptide hydrolysate or a peptide, for example gamma-glutamyl-cysteine, or another form of peptide, for example gamma-glutamyl- cysteine ester, mixed disulfides such as L-cysteine- glutathione cysteine prodrugs, N-acetyl-cysteine (free form, amide or ester forms), S-allyl-cysteine, S- methyl-cysteine, S-ethyl-cysteine , S-propyl-cysteine, TCA (thiazelidineScarboxylic acid), OTC (L-2- Oxothiazolidine-4-carboxylate ) , and S-hydroxy-methyl mercapto L-cysteine.
Cysteine for use in accordance with one of the preceding claims for use in increasing food intake, and/or for decreasing satiety and/or satiation.
Cysteine for use in accordance with one of the preceding claims for increasing appetite.
Cysteine for use in accordance with claim 1, wherein the disorder related to malnutrition is selected from the group consisting of anorexia, anorexia nervosa, cachexia, inflammatory diseases associated with decreased food intake, or combinations thereof.
Cysteine for use in accordance with one of the preceding claims to be administered to an elderly sub ect .
7. Cysteine for use in accordance with one of the preceding claims to treat and/or prevent an age related decrease in food intake.
8. Cysteine for use in accordance with one of the preceding claims, wherein the cysteine is provided in the form of a nutritional composition.
9. Cysteine for use in accordance with one of the preceding claims, wherein the nutritional composition contains a protein fraction comprising at least 3.0 weight-% cysteine, and/or wherein the cysteine is administered in a daily dose in the range of about 0.03 to 0.15 g/kg body weight.
10. Cysteine for use in accordance with one of the preceding claims, wherein the nutritional composition is to be administered orally, enterally or parenterally, and wherein the nutritional composition is to be administered within one hour before a meal, during a meal, or as replacement of a meal.
11. A nutritional composition comprising at least 3.0 weight-% cysteine, preferably at least 4.0 weight-% cysteine, more preferably at least 5.0 weight-% cysteine .
12. The nutritional composition in accordance with claim 11, wherein the nutritional composition has a caloric density of at least 0.5 kcal/g.
13. The nutritional composition in accordance with claim 11 or 12, wherein the nutritional composition comprises about 10 to 40 % of the calories of the nutritional composition from proteins.
14. The nutritional composition in accordance with one of the claims 11 to 13, wherein the nutritional composition comprises about 15 to 45 % of the calories of the nutritional composition from lipids, and/or about 20 to 70 % of the calories of the nutritional composition from carbohydrates.
15. The nutritional composition in accordance with one of the claims 11 to 14, wherein the nutritional composition is selected from the group consisting of a food product, a pet food product, a drink, a pharmaceutical, a nutritional formula, a composition for clinical nutrition, a nutritional powder to be reconstituted by addition of water, a juice or milk, a nutraceutical , a food additive, a food supplement, a dairy product, or a gel.
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES11770786.9T ES2654344T3 (en) | 2010-10-21 | 2011-10-19 | Cysteine and anorexia associated with aging |
| MX2013004371A MX2013004371A (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake. |
| DK11770786.9T DK2629769T3 (en) | 2010-10-21 | 2011-10-19 | CYSTEIN- AND AGE-ASSOCIATED ANOREKSIA |
| SG2013029574A SG189935A1 (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake |
| EP11770786.9A EP2629769B1 (en) | 2010-10-21 | 2011-10-19 | Cysteine and ageing-associated anorexia |
| JP2013534304A JP6160832B2 (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake |
| RU2013123062/15A RU2013123062A (en) | 2010-10-21 | 2011-10-19 | CYSTEINE AND FOOD CONSUMPTION |
| BR112013009709A BR112013009709A2 (en) | 2010-10-21 | 2011-10-19 | cysteine and food absorption |
| AU2011317627A AU2011317627B2 (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake |
| CA2815109A CA2815109C (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake |
| CN2011800614347A CN103269697A (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake |
| US13/880,923 US9233090B2 (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake |
| ZA2013/03656A ZA201303656B (en) | 2010-10-21 | 2013-05-20 | Cysteine and food intake |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10188399.9 | 2010-10-21 | ||
| EP10188399A EP2444083A1 (en) | 2010-10-21 | 2010-10-21 | Cysteine and food intake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012052463A1 true WO2012052463A1 (en) | 2012-04-26 |
Family
ID=43304791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2011/068231 WO2012052463A1 (en) | 2010-10-21 | 2011-10-19 | Cysteine and food intake |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9233090B2 (en) |
| EP (2) | EP2444083A1 (en) |
| JP (1) | JP6160832B2 (en) |
| CN (1) | CN103269697A (en) |
| AU (1) | AU2011317627B2 (en) |
| BR (1) | BR112013009709A2 (en) |
| CA (1) | CA2815109C (en) |
| DK (1) | DK2629769T3 (en) |
| ES (1) | ES2654344T3 (en) |
| MX (1) | MX2013004371A (en) |
| RU (1) | RU2013123062A (en) |
| SG (1) | SG189935A1 (en) |
| WO (1) | WO2012052463A1 (en) |
| ZA (1) | ZA201303656B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024068302A1 (en) | 2022-09-30 | 2024-04-04 | Evonik Operations Gmbh | Probiotic composition for the treatment of malnutrition |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
| EP3668499A1 (en) | 2017-08-14 | 2020-06-24 | Axcella Health Inc. | Amino acid compositions for the treatment of liver disease |
| US20200390793A1 (en) * | 2017-11-21 | 2020-12-17 | Societe Des Produits Nestle S.A. | Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass |
| CN112839643A (en) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | Compositions and methods for treating fat infiltration in muscle |
| WO2020163188A1 (en) * | 2019-02-08 | 2020-08-13 | Imbria Pharmaceuticals, Inc. | Compositions containing n-acetylcysteine conjugated to a tca cycle intermediate |
| EP4049672A4 (en) * | 2019-10-25 | 2023-11-29 | Ajinomoto Co., Inc. | Muscle quality improvement agent |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4665082A (en) * | 1981-02-11 | 1987-05-12 | Cornell Research Foundation | Cysteine delivery system |
| JPS62286923A (en) * | 1986-06-04 | 1987-12-12 | Takao Shinoda | Enhancer for poor appetite action |
| JPH05294833A (en) * | 1991-04-15 | 1993-11-09 | Takeda Chem Ind Ltd | Vitamin-containing health agent |
| US5627152A (en) * | 1995-01-18 | 1997-05-06 | Telluride Pharmaceutical Corporation | Method for increasing bodyweight |
| WO2002015720A2 (en) * | 2000-08-22 | 2002-02-28 | Société des Produits Nestlé S. A. | Nutritional composition an method for improving protein deposition |
| RO119122B1 (en) * | 1998-02-02 | 2004-04-30 | Dumitru Dobrescu | Geriatric medicament |
| US20050215640A1 (en) * | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
| US20090324518A1 (en) * | 2005-12-27 | 2009-12-31 | Consigllo Nazionale Delle Ricerche | Novel Compositions Against Alkyl-Acyul-GPC The Derivatitves and Products Thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993002682A1 (en) * | 1991-08-06 | 1993-02-18 | Labco Pharmaceuticals, Inc. | Method and compositions for reducing craving for alcohol and stimulants |
| DE4229166A1 (en) * | 1992-09-01 | 1994-03-03 | Deutsches Krebsforsch | Means for maintaining and / or increasing muscle performance and body cell mass |
| FR2711529B1 (en) | 1993-10-28 | 1996-07-05 | Clintec Nutrition Cy | Composition based on amino acids intended for the treatment of an infection or an aggression causing an inflammatory reaction, in animals and in humans. |
| US5770217A (en) | 1997-07-02 | 1998-06-23 | Atlatl, Inc. | Dietary supplement for hematological, immune and appetite enhancement |
| IL157367A0 (en) * | 2001-03-09 | 2004-02-19 | Nestle Sa | Composition improving age-related physiological deficits and increasing longevity |
| CA2620313C (en) | 2005-06-14 | 2011-08-02 | Nestec S.A. | Nutritional method for elderly people |
| JP2008201711A (en) * | 2007-02-20 | 2008-09-04 | Ss Pharmaceut Co Ltd | Cysteine odor-reduced solid preparation |
| JP2009001507A (en) | 2007-06-19 | 2009-01-08 | Ss Pharmaceut Co Ltd | Body fat reducing agent and utilization thereof |
| WO2009157759A1 (en) * | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
| TWI515005B (en) * | 2008-09-12 | 2016-01-01 | ２４５８７８１加拿大公司 | Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival |
| EP3461341A1 (en) | 2008-10-17 | 2019-04-03 | Nestec S.A. | Whey protein composition, methods for producing and uses |
-
2010
- 2010-10-21 EP EP10188399A patent/EP2444083A1/en not_active Withdrawn
-
2011
- 2011-10-19 SG SG2013029574A patent/SG189935A1/en unknown
- 2011-10-19 CN CN2011800614347A patent/CN103269697A/en active Pending
- 2011-10-19 US US13/880,923 patent/US9233090B2/en active Active
- 2011-10-19 ES ES11770786.9T patent/ES2654344T3/en active Active
- 2011-10-19 WO PCT/EP2011/068231 patent/WO2012052463A1/en active Application Filing
- 2011-10-19 CA CA2815109A patent/CA2815109C/en active Active
- 2011-10-19 DK DK11770786.9T patent/DK2629769T3/en active
- 2011-10-19 RU RU2013123062/15A patent/RU2013123062A/en not_active Application Discontinuation
- 2011-10-19 MX MX2013004371A patent/MX2013004371A/en not_active Application Discontinuation
- 2011-10-19 AU AU2011317627A patent/AU2011317627B2/en active Active
- 2011-10-19 BR BR112013009709A patent/BR112013009709A2/en not_active Application Discontinuation
- 2011-10-19 EP EP11770786.9A patent/EP2629769B1/en active Active
- 2011-10-19 JP JP2013534304A patent/JP6160832B2/en active Active
-
2013
- 2013-05-20 ZA ZA2013/03656A patent/ZA201303656B/en unknown
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4665082A (en) * | 1981-02-11 | 1987-05-12 | Cornell Research Foundation | Cysteine delivery system |
| JPS62286923A (en) * | 1986-06-04 | 1987-12-12 | Takao Shinoda | Enhancer for poor appetite action |
| JPH05294833A (en) * | 1991-04-15 | 1993-11-09 | Takeda Chem Ind Ltd | Vitamin-containing health agent |
| US5627152A (en) * | 1995-01-18 | 1997-05-06 | Telluride Pharmaceutical Corporation | Method for increasing bodyweight |
| RO119122B1 (en) * | 1998-02-02 | 2004-04-30 | Dumitru Dobrescu | Geriatric medicament |
| WO2002015720A2 (en) * | 2000-08-22 | 2002-02-28 | Société des Produits Nestlé S. A. | Nutritional composition an method for improving protein deposition |
| US20050153019A1 (en) * | 2000-08-22 | 2005-07-14 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
| US20050215640A1 (en) * | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20090324518A1 (en) * | 2005-12-27 | 2009-12-31 | Consigllo Nazionale Delle Ricerche | Novel Compositions Against Alkyl-Acyul-GPC The Derivatitves and Products Thereof |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
Non-Patent Citations (1)
| Title |
|---|
| MBODJI K ET AL: "P233 EFFECT OF A NEW ORAL SUPPLEMENT ENRICHED IN CYSTEINE ON NUTRITIONAL STATUS OF STRESSED RATS", CLINICAL NUTRITION SUPPLEMENTS, ELSEVIER, vol. 4, no. 2, 1 January 2009 (2009-01-01), pages 123, XP026747305, ISSN: 1744-1161, [retrieved on 20090101], DOI: DOI:10.1016/S1744-1161(09)70283-2 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024068302A1 (en) | 2022-09-30 | 2024-04-04 | Evonik Operations Gmbh | Probiotic composition for the treatment of malnutrition |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011317627A1 (en) | 2013-05-23 |
| EP2629769B1 (en) | 2017-10-04 |
| EP2629769A1 (en) | 2013-08-28 |
| MX2013004371A (en) | 2013-08-27 |
| AU2011317627B2 (en) | 2016-06-02 |
| SG189935A1 (en) | 2013-06-28 |
| CA2815109C (en) | 2020-03-24 |
| EP2444083A1 (en) | 2012-04-25 |
| US20130225486A1 (en) | 2013-08-29 |
| JP6160832B2 (en) | 2017-07-12 |
| US9233090B2 (en) | 2016-01-12 |
| ES2654344T3 (en) | 2018-02-13 |
| DK2629769T3 (en) | 2018-01-02 |
| RU2013123062A (en) | 2014-11-27 |
| CN103269697A (en) | 2013-08-28 |
| ZA201303656B (en) | 2014-11-26 |
| JP2014504261A (en) | 2014-02-20 |
| CA2815109A1 (en) | 2012-04-26 |
| BR112013009709A2 (en) | 2016-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011317627B2 (en) | Cysteine and food intake | |
| US20210275582A1 (en) | Composition of nutrition supplementation for nutritional deficiencies and method of use therefore | |
| AU2004222633B2 (en) | Compositions comprising fatty acids and amino acids | |
| WO2012141316A1 (en) | Nutritional composition | |
| JP2007519678A (en) | Nutritional composition for improving skin condition and preventing skin diseases | |
| JP2010506882A (en) | Long-term enteral nutrition for maintenance | |
| JP2014504261A5 (en) | ||
| WO2021086190A1 (en) | Composition comprising epa, ma and leucine for improving muscle function | |
| WO2011042501A2 (en) | The intestine and muscle recovery | |
| JP2019108364A (en) | Nutritive composition | |
| KR20040077682A (en) | Modified methionine rich food products and process for their manufacture | |
| JP2024122087A (en) | Free amino acid absorption enhancer and method for enhancing absorption of free amino acids | |
| JP2020043850A (en) | Antiobestic composition | |
| BR112020019737A2 (en) | use of a composition | |
| JP2019024389A (en) | Amino acid composition for improved muscle strength | |
| WO2013018706A1 (en) | Composition for regulating urat1 activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11770786 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2815109 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/004371 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2013534304 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12013500761 Country of ref document: PH |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13880923 Country of ref document: US |
|
| REEP | Request for entry into the european phase |
Ref document number: 2011770786 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011770786 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2013123062 Country of ref document: RU Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2011317627 Country of ref document: AU Date of ref document: 20111019 Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013009709 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112013009709 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130419 |